GBA
NBSE

Garrison Bradford & Associates’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Garrison Bradford & Associates’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-253
Closed -$9K – 85
2018
Q4 		$9K Sell
253
-770
-75% -$55.8K 0.01% 79
2018
Q3 		$76K Sell
1,023
-105
-9% -$7.91K 0.06% 75
2018
Q2 		$88K Sell
1,128
-78
-6% -$6.81K 0.07% 79
2018
Q1 		$106K Sell
1,206
-20
-2% -$2.97K 0.09% 75
2017
Q4 		$912K Sell
1,226
-18
-1% -$6.95K 0.75% 22
2017
Q3 		$358K Buy
1,244
+1,030
+481% +$281K 0.3% 50
2017
Q2 		$55K Buy
214
+25
+13% +$6.71K 0.05% 82
2017
Q1 		$63K Hold
189
– – 0.06% 81
2016
Q4 		$114K Sell
189
-24
-11% -$25.4K 0.11% 77
2016
Q3 		$241K Sell
213
-13
-6% -$14K 0.23% 63
2016
Q2 		$247K Sell
226
-2
-0.9% -$2.51K 0.24% 63
2016
Q1 		$293K Buy
228
+2
+0.9% +$2.85K 0.34% 49
2015
Q4 		$555K Sell
226
-8
-3% -$12.3K 0.62% 36
2015
Q3 		$258K Buy
234
+20
+9% +$23.2K 0.28% 63
2015
Q2 		$214K Hold
214
– – 0.21% 78
2015
Q1 		$217K Hold
214
– – 0.2% 81
2014
Q4 		$712K Buy
214
+8
+4% +$24.5K 0.65% 35
2014
Q3 		$597K Sell
206
-6
-3% -$19.8K 0.6% 38
2014
Q2 		$805K Buy
+212
New +$798K 0.75% 32

Other funds holding NBSE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIG
Mariner Investment Group Harrison, New York $346M AUM 25.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSB
Sandy Spring Bank Olney, Maryland $2.38B AUM 8.14% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return

Garrison Bradford & Associates's NBSE Position: Q1 2019 in Review

Garrison Bradford & Associates sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2019, closing a stake of 253 shares — an estimated $9K sold.

Garrison Bradford & Associates first reported a position in NBSE in Q2 2014 and held it in 19 quarters. The position peaked at $912K in Q4 2017. 15 funds tracked by Wall St. Rank hold NBSE as of Q1 2019.

  • Garrison Bradford & Associates reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Garrison Bradford & Associates sold 253 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $9K.
  • Garrison Bradford & Associates first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 19 quarters.
  • Garrison Bradford & Associates's NeuBase Therapeutics, Inc. Common Stock position peaked at $912K in Q4 2017.
  • 15 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Garrison Bradford & Associates's 13F filing for Q1 2019, filed 1 May 2019.